胰腺腺癌高频KRAS突变:预后意义和潜在的联合靶向治疗。

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-04-30 Epub Date: 2025-03-24 DOI:10.21037/tcr-24-1832
Jinlong Yu, Dazhi Yan, Xiaorui Liu, Xiaoshi Zhang
{"title":"胰腺腺癌高频KRAS突变:预后意义和潜在的联合靶向治疗。","authors":"Jinlong Yu, Dazhi Yan, Xiaorui Liu, Xiaoshi Zhang","doi":"10.21037/tcr-24-1832","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Kirsten rat sarcoma viral oncogene homolog (KRAS) is among the most frequently mutated oncogenes across multiple cancers. Developing prognostic indicators based on KRAS mutations and advancing targeted KRAS inhibitors remain critical challenges in oncology. Notably, different KRAS mutations are associated with distinct biological behaviors, each carrying unique prognostic and therapeutic implications. The study aims to investigate and explore the characteristics of KRAS mutations and their impact on cancer patient prognosis.</p><p><strong>Methods: </strong>We performed a comprehensive pan-cancer analysis using publicly available The Cancer Genome Atlas (TCGA) Program data to investigate the prognostic significance of KRAS mutations in pancreatic adenocarcinoma (PAAD), colorectal cancer (CRC), and lung adenocarcinoma (LUAD). Kaplan-Meier survival analysis and univariate and multivariate Cox regression models were applied to assess the impact of KRAS mutations on patient outcomes. Additionally, KRAS mutations were detected using Sanger sequencing in genomic DNA extracted from paraffin-embedded tissues of patients enrolled from 2022 to 2024. Mutation rates and their associations with genetic background factors were analyzed.</p><p><strong>Results: </strong>The pan-cancer analysis revealed high KRAS mutation frequencies in PAAD (77.4%), COADREAD (41.1%), and LUAD (27.2%), with the most prevalent mutations being G12C, G12D, and G12V. Sanger sequencing further confirmed the high mutation frequencies of KRAS<sup>G12C, G12D, G12V</sup> in PAAD (54/129), CRC (28/40), and LUAD (24/35). Patients harboring KRAS<sup>G12C, G12D, G12V</sup> mutations in PAAD exhibited significantly reduced overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS), while no significant survival differences were observed in CRC and LUAD. Multivariate Cox regression identified KRAS<sup>G12C, G12D, G12V</sup> as independent prognostic risk factors in PAAD. Moreover, we predict that gefitinib, afatinib, erlotinib, and selumetinib could serve as potential co-targeting therapies for KRAS mutations.</p><p><strong>Conclusions: </strong>KRAS mutations serve as independent prognostic risk factors in PAAD, and targeting these mutations may offer a promising therapeutic approach to improve patient outcomes.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 4","pages":"2331-2342"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079239/pdf/","citationCount":"0","resultStr":"{\"title\":\"High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapies.\",\"authors\":\"Jinlong Yu, Dazhi Yan, Xiaorui Liu, Xiaoshi Zhang\",\"doi\":\"10.21037/tcr-24-1832\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Kirsten rat sarcoma viral oncogene homolog (KRAS) is among the most frequently mutated oncogenes across multiple cancers. Developing prognostic indicators based on KRAS mutations and advancing targeted KRAS inhibitors remain critical challenges in oncology. Notably, different KRAS mutations are associated with distinct biological behaviors, each carrying unique prognostic and therapeutic implications. The study aims to investigate and explore the characteristics of KRAS mutations and their impact on cancer patient prognosis.</p><p><strong>Methods: </strong>We performed a comprehensive pan-cancer analysis using publicly available The Cancer Genome Atlas (TCGA) Program data to investigate the prognostic significance of KRAS mutations in pancreatic adenocarcinoma (PAAD), colorectal cancer (CRC), and lung adenocarcinoma (LUAD). Kaplan-Meier survival analysis and univariate and multivariate Cox regression models were applied to assess the impact of KRAS mutations on patient outcomes. Additionally, KRAS mutations were detected using Sanger sequencing in genomic DNA extracted from paraffin-embedded tissues of patients enrolled from 2022 to 2024. Mutation rates and their associations with genetic background factors were analyzed.</p><p><strong>Results: </strong>The pan-cancer analysis revealed high KRAS mutation frequencies in PAAD (77.4%), COADREAD (41.1%), and LUAD (27.2%), with the most prevalent mutations being G12C, G12D, and G12V. Sanger sequencing further confirmed the high mutation frequencies of KRAS<sup>G12C, G12D, G12V</sup> in PAAD (54/129), CRC (28/40), and LUAD (24/35). Patients harboring KRAS<sup>G12C, G12D, G12V</sup> mutations in PAAD exhibited significantly reduced overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS), while no significant survival differences were observed in CRC and LUAD. Multivariate Cox regression identified KRAS<sup>G12C, G12D, G12V</sup> as independent prognostic risk factors in PAAD. Moreover, we predict that gefitinib, afatinib, erlotinib, and selumetinib could serve as potential co-targeting therapies for KRAS mutations.</p><p><strong>Conclusions: </strong>KRAS mutations serve as independent prognostic risk factors in PAAD, and targeting these mutations may offer a promising therapeutic approach to improve patient outcomes.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 4\",\"pages\":\"2331-2342\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079239/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-1832\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1832","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)是多种癌症中最常见的突变癌基因之一。开发基于KRAS突变的预后指标和推进靶向KRAS抑制剂仍然是肿瘤学的关键挑战。值得注意的是,不同的KRAS突变与不同的生物学行为相关,每种突变都具有独特的预后和治疗意义。本研究旨在调查和探讨KRAS突变的特点及其对癌症患者预后的影响。方法:我们利用公开的癌症基因组图谱(TCGA)项目数据进行了一项全面的泛癌症分析,以研究KRAS突变在胰腺腺癌(PAAD)、结直肠癌(CRC)和肺腺癌(LUAD)中的预后意义。应用Kaplan-Meier生存分析以及单因素和多因素Cox回归模型来评估KRAS突变对患者预后的影响。此外,从2022年至2024年入选的患者的石蜡包埋组织中提取的基因组DNA中,使用Sanger测序检测KRAS突变。分析突变率及其与遗传背景因素的关系。结果:泛癌分析显示,KRAS在PAAD(77.4%)、COADREAD(41.1%)和LUAD(27.2%)中突变频率较高,其中最常见的突变是G12C、G12D和G12V。Sanger测序进一步证实了KRASG12C、G12D、G12V在PAAD(54/129)、CRC(28/40)和LUAD(24/35)中的高突变频率。在PAAD中携带KRASG12C、G12D、G12V突变的患者表现出显著降低的总生存期(OS)、无进展生存期(PFS)和无病生存期(DFS),而在CRC和LUAD中没有观察到显著的生存差异。多因素Cox回归分析发现KRASG12C、G12D、G12V是PAAD的独立预后危险因素。此外,我们预测吉非替尼、阿法替尼、厄洛替尼和塞鲁美替尼可能作为KRAS突变的潜在共靶向治疗药物。结论:KRAS突变是PAAD的独立预后危险因素,靶向这些突变可能提供一种有希望的治疗方法来改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapies.

Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) is among the most frequently mutated oncogenes across multiple cancers. Developing prognostic indicators based on KRAS mutations and advancing targeted KRAS inhibitors remain critical challenges in oncology. Notably, different KRAS mutations are associated with distinct biological behaviors, each carrying unique prognostic and therapeutic implications. The study aims to investigate and explore the characteristics of KRAS mutations and their impact on cancer patient prognosis.

Methods: We performed a comprehensive pan-cancer analysis using publicly available The Cancer Genome Atlas (TCGA) Program data to investigate the prognostic significance of KRAS mutations in pancreatic adenocarcinoma (PAAD), colorectal cancer (CRC), and lung adenocarcinoma (LUAD). Kaplan-Meier survival analysis and univariate and multivariate Cox regression models were applied to assess the impact of KRAS mutations on patient outcomes. Additionally, KRAS mutations were detected using Sanger sequencing in genomic DNA extracted from paraffin-embedded tissues of patients enrolled from 2022 to 2024. Mutation rates and their associations with genetic background factors were analyzed.

Results: The pan-cancer analysis revealed high KRAS mutation frequencies in PAAD (77.4%), COADREAD (41.1%), and LUAD (27.2%), with the most prevalent mutations being G12C, G12D, and G12V. Sanger sequencing further confirmed the high mutation frequencies of KRASG12C, G12D, G12V in PAAD (54/129), CRC (28/40), and LUAD (24/35). Patients harboring KRASG12C, G12D, G12V mutations in PAAD exhibited significantly reduced overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS), while no significant survival differences were observed in CRC and LUAD. Multivariate Cox regression identified KRASG12C, G12D, G12V as independent prognostic risk factors in PAAD. Moreover, we predict that gefitinib, afatinib, erlotinib, and selumetinib could serve as potential co-targeting therapies for KRAS mutations.

Conclusions: KRAS mutations serve as independent prognostic risk factors in PAAD, and targeting these mutations may offer a promising therapeutic approach to improve patient outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信